European Medicines Agency (EMA) recommends approval of Harvoni, Gilead’s all oral HCV combination product

The European Medicines Agency (EMA) is recommending approval of Harvoni, a combination of 9mg of ledipasvir (LDV) and 400mg of sofosbuvir (SOF), for the treatment of chronic hepatitis C virus (HCV) infection in adults. This is the “all oral” combination product, delivered in daily does of just 490 mg of API, for the “cure of patients with chronic HCV infection without the need for treatments involving interferons.”

Continue Reading

Uncategorized

WIPO General Assembly 2014: KEI Statement on the Standing Committee on the Law of Patents

On Thursday, 25 September 2014, Knowledge Ecology International (KEI) delivered this statement on agenda item 17(i), Reports on other WIPO Committees, (i) Standing on the Law of Patents (SCP).

WIPO General Assembly 2014

17. Reports on other WIPO Committees
(i) Standing Committee on the Law of Patents (SCP);

Statement of Knowledge Ecology International

Continue Reading

Uncategorized

WIPO General Assembly 2014: South Africa Intervention on the Standing Committee on the Law of Patents (SCP)

On Thursday, 25 September 2014, South Africa delivered the following intervention on agenda item 17(i) on the Report of the Standing Committee on the Law of Patents (SCP) at the Fifty-Fourth Series of Meetings of the Assemblies of the Member States of WIPO.

South Africa Intervention on the Standing Committee on the Law of Patents (SCP)

Continue Reading

Uncategorized

WIPO General Assembly 2014: KEI statement on Matters Relating to the Standing Committee on Copyright and Related Rights (SCCR)

On Wednesday, 24 September 2014, Knowledge Ecology International delivered this intervention on agenda item 15, Matters Relating to the Standing Committee on Copyright and Related Rights (SCCR)

WIPO General Assembly 2014

15. Matters Relating to the Standing Committee on Copyright and Related Rights (SCCR)

Statement of Knowledge Ecology International

Continue Reading

Uncategorized

WIPO General Assembly 2014: KEI statement on the Report of the Committee on Development and Intellectual Property (CDIP)

On Wednesday, 24 September 2014, Knowledge Ecology International delivered the following statement at the 2014 WIPO General Assembly on agenda item 13, Report of the Committee on Development and Intellectual Property (CDIP) and Review of the Implementation of the Development Agenda Recommendations.

13. Report of the Committee on Development and Intellectual Property (CDIP) and Review of the Implementation of the Development Agenda Recommendations

Statement of Knowledge Ecology International

Continue Reading

Uncategorized

Comments of KEI regarding the White House OSTP call for comments on its Strategy for American Innovation

Comments of KEI regarding the White House OSTP call for comments on its Strategy for American Innovation

(PDF of comments here)

Attn: Dan Correa, Office of Science and Technology Policy, Eisenhower Executive Office Building, 1650 Pennsylvania Ave NW., Washington, DC 20504.
Email: innovationstrategy@ostp.gov.
Re: Strategy for American Innovation
Date: September 23, 2014

Continue Reading

Uncategorized

FDA creates $500k prize for technology to improve detection of Salmonella

This just published by the US FDA:

The U.S. Food and Drug Administration is asking for potential breakthrough ideas on how to find disease-causing organisms in food – especially Salmonella in fresh produce.

The 2014 FDA Food Safety Challenge was developed under the America COMPETES Reauthorization Act of 2010, which grants all federal agencies broad authority to conduct prize competitions to spur innovation, solve tough problems, and advance their core missions. This challenge offers a total prize pool of $500,000.

Continue Reading

Uncategorized

WIPO General Assembly 2014: Opening Statement of Knowledge Ecology International

On Tuesday, 23 September 2014, Knowledge Ecology International (KEI) delivered this opening statement on the occasion of the Fifty-Fourth Series of Meetings of the Assemblies of the Member States of the World Intellectual Property Organization (WIPO).

Thank you Madame Chair for providing Knowledge Ecology International (KEI) the opportunity to speak today.

Continue Reading

Uncategorized

Bayer’s rejection of request for affordable Nexavar for Fathi Helmi Aboseda (Egypt)

Today we received news from Nina Mahmud that her father-in-law, Fathi Helmi Aboseda, has passed away in Egypt. Mr. Aboseda was suffering from liver cancer. Earlier this year, Nina Mahmud had contacted Bayer and KEI asking for help in finding affordable copies of sorafenib, a drug for liver and kidney cancer sold by Bayer under the trade name Nexavar, a drug that was extending and improving the quality of his life. The price of Nexavar in Egypt was $900 per week, and Mr. Aboseda had used his entire life savings to buy the drug.

Continue Reading